Outbreaks of iatrogenic Botulism in Europe: Combating Off-Label Medical Use of Botulinum Neurotoxin (BoNT) in Bariatric Procedures

Nityanand Jain; Edouard Lansiaux; Umut Yucel; Swantje Hunermund; Stella Goeschl; Patricia Schlagenhauf

doi:10.1016/j.nmni.2023.101152

Outbreaks of iatrogenic Botulism in Europe: Combating Off-Label Medical Use of Botulinum Neurotoxin (BoNT) in Bariatric Procedures

Nityanand Jain (Corresponding Author)
, Edouard Lansiaux
, Umut Yucel
, Swantje Hunermund
, Stella Goeschl
, Patricia Schlagenhauf (Editor-in-chief)

Faculty of Medicine

Research output: Contribution to journal › Editorial

10 Citations (Scopus)

Abstract

In late March 2023, the World Health Organization (WHO) issued a disease outbreak notification regarding an iatrogenic outbreak of botulism in 87 patients who underwent bariatric (weight-loss) procedures at two Turkish hospitals. In this editorial, we look at the current outbreak situation, the availability of Botulism Neurotoxin (BoNT) in Turkiye, patient identification, and management. We further discuss the state of current evidence on the effectiveness of BoNT injections for weight loss and the public health response due to the current outbreaks.

Original language	English
Article number	101152
Pages (from-to)	1-4
Number of pages	4
Journal	New Microbes and New Infections
Volume	53
DOIs	https://doi.org/10.1016/j.nmni.2023.101152
Publication status	Published - Jun 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords*

botulism
Europe
off-label
bariatric
weight loss

Field of Science*

3.2 Clinical medicine
3.3 Health sciences

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

Access to Document

10.1016/j.nmni.2023.101152Licence: CC BY

https://www.sciencedirect.com/science/article/pii/S2052297523000719Licence: CC BY

Cite this

@article{a53841cec0b840898107d23bc7d39107,

title = "Outbreaks of iatrogenic Botulism in Europe: Combating Off-Label Medical Use of Botulinum Neurotoxin (BoNT) in Bariatric Procedures",

abstract = "In late March 2023, the World Health Organization (WHO) issued a disease outbreak notification regarding an iatrogenic outbreak of botulism in 87 patients who underwent bariatric (weight-loss) procedures at two Turkish hospitals. In this editorial, we look at the current outbreak situation, the availability of Botulism Neurotoxin (BoNT) in Turkiye, patient identification, and management. We further discuss the state of current evidence on the effectiveness of BoNT injections for weight loss and the public health response due to the current outbreaks. ",

keywords = "botulism, Europe, off-label, bariatric, weight loss",

author = "Nityanand Jain and Edouard Lansiaux and Umut Yucel and Swantje Hunermund and Stella Goeschl and Patricia Schlagenhauf",

note = "Funding Information: Not applicable.",

year = "2023",

month = jun,

doi = "10.1016/j.nmni.2023.101152",

language = "English",

volume = "53",

pages = "1--4",

journal = "New Microbes and New Infections",

issn = "2052-2975",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - Outbreaks of iatrogenic Botulism in Europe

T2 - Combating Off-Label Medical Use of Botulinum Neurotoxin (BoNT) in Bariatric Procedures

AU - Jain, Nityanand

AU - Lansiaux, Edouard

AU - Yucel, Umut

AU - Hunermund, Swantje

AU - Goeschl, Stella

A2 - Schlagenhauf, Patricia

N1 - Funding Information: Not applicable.

PY - 2023/6

Y1 - 2023/6

N2 - In late March 2023, the World Health Organization (WHO) issued a disease outbreak notification regarding an iatrogenic outbreak of botulism in 87 patients who underwent bariatric (weight-loss) procedures at two Turkish hospitals. In this editorial, we look at the current outbreak situation, the availability of Botulism Neurotoxin (BoNT) in Turkiye, patient identification, and management. We further discuss the state of current evidence on the effectiveness of BoNT injections for weight loss and the public health response due to the current outbreaks.

AB - In late March 2023, the World Health Organization (WHO) issued a disease outbreak notification regarding an iatrogenic outbreak of botulism in 87 patients who underwent bariatric (weight-loss) procedures at two Turkish hospitals. In this editorial, we look at the current outbreak situation, the availability of Botulism Neurotoxin (BoNT) in Turkiye, patient identification, and management. We further discuss the state of current evidence on the effectiveness of BoNT injections for weight loss and the public health response due to the current outbreaks.

KW - botulism

KW - Europe

KW - off-label

KW - bariatric

KW - weight loss

UR - https://www.scopus.com/pages/publications/85160217405

U2 - 10.1016/j.nmni.2023.101152

DO - 10.1016/j.nmni.2023.101152

M3 - Editorial

SN - 2052-2975

VL - 53

SP - 1

EP - 4

JO - New Microbes and New Infections

JF - New Microbes and New Infections

M1 - 101152

ER -

Outbreaks of iatrogenic Botulism in Europe: Combating Off-Label Medical Use of Botulinum Neurotoxin (BoNT) in Bariatric Procedures

Abstract

UN SDGs

Keywords*

Field of Science*

Publication Type*

Access to Document

Other files and links

Fingerprint

Cite this